




# CB in Brief



## The Competition Bureau's Month in Review

### November 2010

#### News

#### Teva / Ratiopharm Divests Products Pursuant to the Terms of Consent Agreement

The Competition Bureau is pleased to announce that Teva Pharmaceutical Industries Ltd. has completed the divestiture of assets and associated licences relating to the sale and supply of certain generic drugs to Sandoz Canada Inc., in accordance with the terms of a July 2010 Consent Agreement with the Bureau.

The Bureau concluded that the merger of Teva and the Merckle Group (carrying on business as ratiopharm) would likely lead to a substantial lessening of competition in the sale and supply of acetaminophen oxycodone tablets and morphine-sulfate sustained-release tablets in Canada, which are used for moderate-to-severe pain relief.

#### Recent Announcements

- **November 22, 2010**  
[Competition Bureau to Issue Revised Fee and Service Standards Handbook](#)
- **November 19, 2010**  
[Competition Bureau Takes Action Against Rogers Over Misleading Advertising](#)
- **November 3, 2010**  
[Panasonic Corporation Pleads Guilty to Price-Fixing Conspiracy October 5, 2010](#)

> For enquiries or information, please contact:  
[Phil Norris](#) - Communications.

- > CB in Brief is an electronic publication, distributed regularly to media and stakeholders to provide a snapshot of recent news and developments.
- > The Competition Bureau is an independent law enforcement agency that contributes to the prosperity of Canadians by protecting and promoting competitive markets and enabling informed consumer choice.



[Information Centre](#)



[Competition Bureau Media Centre](#)




[Competition Bureau Home](#)

ISSN 1923-2292  
Vol. 2, No. 11

Industry Canada  
Library - Queen

SEP 17 2012

Industrie Canada  
Bibliothèque - Queen



Canada 